Q-omics provides the consensus-scored RNF207 profile across patient tissues and cancer cell-line models. RNF207 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, RNF207 is differentially expressed in 14, with the highest sampling consensus in LUAD. Additionally, RNF207 RNA expression shows 19,341 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, LUAD, and UVM as cancer lineages where RNF207 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNF207 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNF207 survival associations across molecular data types. RNF207 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNF207 RNA expression–survival associations across cancer types. High RNF207 expression shows unfavorable associations in KIRC, ACC, KICH and COAD, but favorable associations in BLCA and BRCA. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for RNF207 RNA expression.
This table summarizes RNF207 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for RNF207. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNF207 shows higher tumor expression in LUAD, STAD, LIHC, COAD, BLCA and PAAD. The LUAD box plot shows higher RNF207 RNA expression in tumor versus normal tissue (log2 FC = +0.658, t-test p < 0.001).
This table shows molecular features associated with RNF207 in patient tissues and cancer cell lines. In patient samples, RNF207 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, RNF207 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and LARGE_INTESTINE.
